Expanding Day One’s pipeline with pimasertib

Pimasertib is an investigational, highly selective, oral, small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK) within the MAPK signaling pathway.

To date, pimasertib has been dosed in over 850 patients across more than 10 Phase 1/2 clinical trials for various tumor types. Preclinical data indicates that the combination of a MEK inhibitor, such as pimasertib, and a type II RAF inhibitor may have synergistic anti-tumor activity.

We have initiated a Phase 1/2 study (FIRELIGHT-1) to evaluate the safety, tolerability, and preliminary efficacy of combining pimasertib with tovorafenib in adolescent and adult patients (≥12 years of age) with recurrent, progressive, or refractory solid tumors with MAPK pathway aberrations.

See our progress in motion.